Achieving Better Advocacy Group Relationships, a Critical Piece of Resurgent Disease State Awareness Drive in Pharmaceutical Industry

JEFF ZIMMER | February 3, 2017

article image
When it comes to informing physicians and patients about new therapies, disease awareness programs have experienced a rebirth in the pharmaceutical industry. For decades, disease awareness campaigns were a part of the playbook for educating physicians and patients about new products. But, awareness programs receded in the long shadow cast by Direct-to-Consumer (DTC) marketing after the FDA, in 1985, explicitly allowed TV drug advertising.

Spotlight

Jarun Pharmaceuticals Pvt. Ltd.

We Take The Opportunity To Introduce Ourselves As Up-Comming Pharmaceutical Marketing Company From Ahmedabad. We Are One Of The Group Companies Of J.J. Parikh & Bros and J. Bipinchandra & co. Who Enjoys 60 Years Of Reputation As Leading Distribution House Of Gujarat, With Annual Turn-Over Of More Than 40 Crores.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | February 17, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | February 17, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | February 17, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

Jarun Pharmaceuticals Pvt. Ltd.

We Take The Opportunity To Introduce Ourselves As Up-Comming Pharmaceutical Marketing Company From Ahmedabad. We Are One Of The Group Companies Of J.J. Parikh & Bros and J. Bipinchandra & co. Who Enjoys 60 Years Of Reputation As Leading Distribution House Of Gujarat, With Annual Turn-Over Of More Than 40 Crores.

Events